[Hospital admissions in Chile among patients with Parkinson's disease from 2001 to 2018]

Pedro Chana-Cuevas1, Francisco Ormazábal2

  • 1Facultad de Ciencias Médicas, Universidad de Santiago de Chile, Santiago, Chile.

Revista Medica De Chile
|June 23, 2022
PubMed

Insights

Hospitalizations for Parkinson's disease in Chile decreased significantly from 2001 to 2018. This decline in Parkinson's disease hospitalizations may be linked to improved access to care.

Area of Science:

  • Neurology
  • Public Health
  • Health Services Research

Background:

  • Parkinson's disease progression involves complications, many of which are preventable.
  • Understanding hospitalization trends is crucial for managing Parkinson's disease.

Purpose of the Study:

  • To analyze hospitalizations for Parkinson's disease (ICD 10 code G20) in Chile.
  • To compare hospitalization patterns across different Chilean health subsystems.

Main Methods:

  • Utilized Chilean Ministry of Health hospital discharge data from 2001 to 2018.
  • Analyzed discharges with a primary diagnosis of Parkinson's disease.

Main Results:

  • The hospitalization rate for Parkinson's disease decreased from 55.2 to 29.8 per 100,000 between 2001 and 2018.
  • Public sector admissions (FONASA beneficiaries) constituted 67% of cases, while private insurance accounted for 12%.
  • The average hospital stay was 13.4 days.

Conclusions:

  • A notable decrease in Parkinson's disease hospitalizations was observed over time.
  • This trend may correlate with a government program ensuring timely diagnosis and treatment access for Parkinson's disease.
Abstract

Related Concept Videos

Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
371
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
700
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
260
Neural Regulation01:37

Neural Regulation

Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.8K